🔗 Share this article

While the United States undertakes historic revisions to its vaccine schedules, one figure appears unexpectedly: Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by questioning COVID-19 shots in the pandemic and has zeroed in on alleged fatalities after COVID-19 vaccination in her brief position at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Schedule

Health officials planned to announce radical changes to the childhood vaccine schedule in December, synchronizing the US with the Danish national calendar, according to reports – a major change that would place the US out of alignment with a large portion of the global community with insufficient data for benefit. The announcement has been pushed back until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to speak at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this year.

Consolidating Power at the Agency

This interim role may indicate a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon rolling back already-approved immunizations at the FDA.

Høeg has repeatedly called for halting certain pediatric immunization guidelines in the US to become more like the Danish model, a society with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Concerns Over Background

The appointee has no apparent track record in medication creation, approval processes or administrative roles, which has been standard for past heads of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, said Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She is not an expert in industry regulation.”

Past directors of the center would “be deeply familiar with laws and regulations and the research of medication creation”, commented a former acting FDA commissioner. “Clearly, she lacks the type of experience that former directors who ran the center have had.”

The drug center has an vast workload at the agency, she emphasized.

“Everybody just zeroes in on the new drug program, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and more, and all of those must be supervised,” she explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership aspect to the position, which manages in excess of 5,000 employees. “It is a enormous administrative position, if you execute it properly,” the former official said.

Agency Reaction and Controversial Initiatives

Regarding concerns about Høeg’s qualifications and whether this assignment represents increased cooperation among FDA leaders on immunizations, a spokesperson stated that the “concerns stem from inaccurate premises”.

“This background is consistent with the functions of her job,” the official explained, pointing to the time Høeg spent advising the FDA commissioner on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a disputed rapid medication authorization process that apparently troubled her former heads. “How are these medications being chosen for this voucher program? Who makes the decisions?” Dr. Howard said. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards more relaxed oversight of pharmaceuticals, aside from vaccines.”

Documented Past Work on Vaccines

Regarding immunizations, Høeg has a more documented, if problematic, history, some experts observe. She published a analysis using non-validated volunteer-provided data to determine the incidence of heart inflammation after COVID-19 immunization. She advised the Florida chief medical officer Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are more dangerous than they are.

Part of her “wish list” for the current government included changing guidelines for novel immunizations and halting “optional” vaccines, she said after the election on a audio program. At the FDA, Høeg has allegedly suggested excluding adolescent males from receiving Covid vaccinations.

“She’s an complete dogmatist who commences with her conclusions and tailors the evidence to accommodate the evidence in a extremely disingenuous, dishonest manner,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|